publications-banner

Information about pipeline products

PublicationView

HER3-DXd
Lung Cancer
Current and emerging treatment options for patients with metastatic EGFR-mutated non-small cell lung cancer after progression on osimertinib and platinum-based chemotherapy: A podcast discussion
Patel S, Patel JD.
Adv Ther. 2023;40(12):5579-5590.
T-DXd
Lung Cancer
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
Baba T, Kusumoto M, Kato T, et al.
Baba et al. Int J Clin Oncol. 2023 Dec;28(12):1585-1596. doi: 10.1007/s10147-023-02414-x. Epub 2023 Oct 3.
HER3-DXd
Lung Cancer
EGFR mutations are not all the same: The importance of biomarker testing in non-small cell lung cancer (NSCLC)—a podcast discussion between patients and oncologists
Liu SV, Elkins IB, Feldman J, Goldberg SB.
Oncol Ther. 2023;11(4):419-431.
Edoxaban
Cardiovascular - AF
Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: The ETNA-AF-Europe registry
Schnabel RB, Ameri P, Siller-Matula JM, et al.
EP Europace. 2023;25(9):euad280.
Valemetostat
Hematology
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects
Tachibana M, Matsuki S, Maekawa Y, et al.
Clin Transl Sci. 2023;16(11):2153-2162.
Edoxaban
Cardiovascular - AF Cardiovascular - VTE
Predictive factors and clinical events associated with edoxaban interruption and heparin bridging strategy: EMIT-AF/VTE
Santamaria A, Chen C, Colonna P, et al.
Clin Appl Thromb Hemost. 2023;29:10760296.
T-DXd
Lung Cancer
Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial
Goto K, Goto Y, Kubo T, et al.
J Clin Oncol. 2023;41(31):4852-4863.
HER3-DXd
Lung Cancer
HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy
Yu HA, Goto Y, Hayashi H, et al.
J Clin Oncol. 2023;41(35):5363-5375.
Edoxaban
Cardiovascular - VTE
Incidence and risk factors for venous thromboembolism in the Cancer-VTE registry pancreatic cancer subcohort
Okusaka T, Saiura A, Shimada K, et al.
J Gastroenterol. 2023;58(12):1261-1271.
HER3-DXd
Lung Cancer
Treatment patterns and adverse event-related hospitalization among patients with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer after treatment with EGFR tyrosine kinase inhibitor and platinum-based chemotherapy regimens
Marrett E, Kwong JW, Xie J, et al.
Drugs Real World Outcomes. 2023;10(4):531-544.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer